Xenon to Report Q1 2025 Financial Results on May 12, 2025
Xenon Pharmaceuticals (Nasdaq: XENE) has scheduled to release its first quarter 2025 financial results and provide a business update after U.S. market close on Monday, May 12, 2025. The company will host a conference call at 4:30 pm Eastern Time on the same day.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE) ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale dopo la chiusura del mercato statunitense di lunedì 12 maggio 2025. La società terrà una conference call alle 16:30 ora della costa orientale degli Stati Uniti nello stesso giorno.
Xenon è un'azienda biofarmaceutica specializzata in neuroscienze che sviluppa prodotti per canali ionici destinati a trattare epilessia e depressione. Il loro candidato principale, azetukalner, è un apritore del canale potassio Kv7 in fase avanzata di sviluppo clinico per diverse indicazioni.
Xenon Pharmaceuticals (Nasdaq: XENE) ha programado publicar sus resultados financieros del primer trimestre de 2025 y ofrecer una actualización empresarial tras el cierre del mercado estadounidense el lunes 12 de mayo de 2025. La compañía realizará una llamada conferencia a las 4:30 pm hora del Este ese mismo día.
Xenon es una empresa biofarmacéutica centrada en neurociencia que desarrolla productos para canales iónicos para epilepsia y depresión. Su candidato principal, azetukalner, es un activador del canal de potasio Kv7 en fase avanzada de desarrollo clínico para múltiples indicaciones.
Xenon Pharmaceuticals (나스닥: XENE)는 2025년 1분기 재무 실적과 사업 업데이트를 2025년 5월 12일 월요일 미국 시장 마감 후 발표할 예정입니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜을 진행합니다.
Xenon은 뇌과학에 중점을 둔 바이오제약 회사로, 간질 및 우울증 치료를 위한 이온 채널 제품을 개발하고 있습니다. 주력 후보물질인 azetukalner는 다중 적응증에 대해 후기 임상 개발 중인 Kv7 칼륨 채널 개방제입니다.
Xenon Pharmaceuticals (Nasdaq : XENE) prévoit de publier ses résultats financiers du premier trimestre 2025 et de fournir une mise à jour commerciale après la clôture du marché américain le lundi 12 mai 2025. La société organisera une conférence téléphonique à 16h30, heure de l'Est, le même jour.
Xenon est une entreprise biopharmaceutique spécialisée en neurosciences, développant des produits ciblant les canaux ioniques pour l'épilepsie et la dépression. Leur principal candidat, azetukalner, est un activateur des canaux potassiques Kv7 en phase avancée de développement clinique pour plusieurs indications.
Xenon Pharmaceuticals (Nasdaq: XENE) plant die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 sowie ein Unternehmensupdate nach Börsenschluss in den USA am Montag, den 12. Mai 2025. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten.
Xenon ist ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften, das Ionkanal-Produkte für Epilepsie und Depression entwickelt. Ihr führender Kandidat, azetukalner, ist ein Kv7-Kaliumkanalöffner in der späten klinischen Entwicklungsphase für mehrere Indikationen.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025.
| Conference Call/Webcast Information: | |
| Date: | Monday, May 12, 2025 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Webcast: | Pre-register here |
| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers |
| Conference ID: | 5532604 |
A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When will Xenon Pharmaceuticals (XENE) report Q1 2025 earnings?
What time is Xenon's (XENE) Q1 2025 earnings conference call?
What is Xenon Pharmaceuticals' (XENE) main drug candidate?
What therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?
